Chemical Characterization in Biocompatibility
Understanding the cornerstone of modern biocompatibility evaluation and its critical role in patient safety and regulatory compliance.
Chemical characterization has become a cornerstone of modern biocompatibility evaluation. Regulatory authorities now expect medical device manufacturers to understand exactly what chemicals may be released from a device and how those chemicals could impact patient safety. With the increased focus on risk-based and science-driven evaluation in ISO 10993-1:2025, chemical characterization under ISO 10993-18 plays a critical role.
In this blog, Accuprec Research Labs Pvt. Ltd. explains what chemical characterization is, why it is essential and how ISO 10993-18 supports regulatory-compliant biocompatibility assessment.
Chemical characterization is the process of identifying and evaluating chemical substances that may be released from a medical device under normal or worst-case conditions of use. It focuses on extractables and leachables that could potentially expose patients to harmful substances.
This evaluation forms the scientific foundation for toxicological risk assessment and biological safety decisions.
ISO 10993-18 provides guidance on:
- Selection of extraction conditions
- Analytical methods for chemical identification
- Reporting and interpretation of results
It works closely with ISO 10993-1 and ISO 10993-17 to support a complete, risk-based biocompatibility strategy.
Regulatory expectations have evolved significantly. Authorities now expect manufacturers to understand material composition, identify potential chemical hazards, estimate patient exposure, and use scientific data to justify safety. Chemical characterization allows manufacturers to meet these expectations efficiently.
Extractables
Extractables are chemicals that can be released from a device under aggressive laboratory conditions. They help identify potential worst-case risks.
Leachables
Leachables are chemicals released under actual conditions of use. They represent realistic patient exposure. Both are important for comprehensive safety assessment.
A strong chemical characterization strategy includes the selection of representative samples, appropriate extraction solvents, relevant temperatures, durations, and sensitive analytical techniques. Common methods include:
- Gas chromatography (GC-MS): For volatile and semi-volatile organic compounds.
- Liquid chromatography (LC-MS): For non-volatile organic substances.
- Inductively coupled plasma (ICP-MS): For inorganic substances and metals.
These techniques help identify substances accurately to ensure the study design reflects device use and patient exposure.
Chemical characterization data is used to identify chemicals of concern, estimate patient exposure, and compare exposure to toxicological thresholds. This information supports toxicological risk assessment under ISO 10993-17.
Regulators expect studies to be scientifically justified, device-specific, transparent, and well-documented. Poor design often leads to questions. Manufacturers may face challenges such as complex material compositions, low-level chemical detection, and interpretation of analytical data. Expert support helps ensure accurate and acceptable results.
- Reduced reliance on animal testing
- Strong scientific justification for safety
- Faster regulatory reviews
- Improved patient safety assurance
It also supports lifecycle management and design changes.
Accuprec Research Labs Pvt. Ltd. provides comprehensive services, including ISO 10993-18–compliant study design, advanced analytical testing, data interpretation, and support for toxicological risk assessment. Our expertise ensures regulatory-ready and reliable results.
Chemical characterization under ISO 10993-18 is a fundamental component of modern biocompatibility evaluation. With increasing regulatory emphasis on risk-based and science-driven approaches, chemical characterization enables manufacturers to assess safety accurately while reducing unnecessary testing.
By adopting strong chemical characterization strategies, medical device manufacturers can improve regulatory outcomes and ensure patient safety.
